Pfizer DMD Gene Therapy Phase III Trial Stalled In US After FDA Questions On Potency Assays
Pfizer disclosed that a Phase III trial for the gene therapy has been unable to start in the US because of questions from the FDA, even while enrollment in 15 sites outside the US is under way.
You may also be interested in...
The company has initiated the first pivotal double-blind gene therapy trial in DMD in the US in a tight race with Pfizer.
Investors are trying to wrap their minds around exactly how big Pfizer’s COVID vaccine business will end up being. But they also have questions about Pfizer’s prospects at the opposite end of the patient-population spectrum.
Pfizer said it expects to generate $26bn in annual revenues from the COVID-19 vaccine BNT162b2 and is leveraging the platform to build out a durable business.